SARAH SANKEY: Open Payments
NPI 1710521687 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$480 in 26 payments from 15 companies in 2025. Trend: 2023 $922 · 2024 $604 · 2025 $480
Food & beverage: $480
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $77 |
| Verona Pharma, Inc. | 3 | $56 |
| Medtronic, Inc. | 2 | $55 |
| Insmed, Inc. | 2 | $51 |
| GENZYME CORPORATION | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Grifols USA, LLC | 1 | $23 |
| GlaxoSmithKline, LLC. | 1 | $21 |
| Edwards Lifesciences Corporation | 1 | $20 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $18 |
Products named: FASENRA, DUPIXENT, Ohtuvayre, ILLUMISITE, Arikayce, Prolastin-C Liquid, TRELEGY ELLIPTA, ARALAST.
Industry payments across NE — which companies pay providers there.
